TEF3 Antibody

What is TEF3 and why is it important in cellular research?

TEF3 (Transcription Enhancer Factor 3) is a transcription factor that regulates gene expression by binding to specific DNA sequences. TEF3 has been identified as a critical regulator of cell cycle progression, particularly in G1/S transition in endothelial cells. Microarray analyses have demonstrated that TEF3-1 (a TEF3 isoform) overexpression upregulates genes related to cell cycle progression and angiogenesis promotion . The nuclear localization of TEF3-1 is particularly important, as it stimulates cell cycle progression in Human Umbilical Vein Endothelial Cells (HUVECs) and contributes specifically to tumor angiogenesis . Understanding TEF3's functions provides valuable insights into fundamental cellular processes and potential therapeutic targets in cancer research.

How do I select the appropriate TEF3 antibody for my specific experimental design?

Selection of the appropriate TEF3 antibody depends on several factors:

• Target epitope: Different TEF3 antibodies target different regions of the protein. For example, some antibodies target the C-terminal region (AA 489-516), while others target the N-terminal (AA 1-30) or internal regions . The choice depends on which protein domain is accessible in your experimental conditions and which isoform you wish to detect.

• Host species: Consider the host species of your antibody (e.g., rabbit, mouse, goat) to avoid cross-reactivity in multi-color immunostaining experiments .

• Clonality: Polyclonal antibodies offer higher sensitivity by recognizing multiple epitopes, while monoclonal antibodies provide higher specificity for a single epitope .

• Application compatibility: Ensure the antibody has been validated for your specific application (Western blot, immunohistochemistry, immunofluorescence, ELISA, etc.) .

• Species reactivity: Verify that the antibody reacts with your experimental species (human, mouse, rat, etc.) .

For experiments focusing on nuclear localization of TEF3-1, which is critical for its role in cell cycle progression, choose antibodies specifically validated for detecting nuclear TEF3 .

What are the optimal conditions for using TEF3 antibodies in Western blotting?

For optimal Western blotting results with TEF3 antibodies:

• Sample preparation: Efficient nuclear protein extraction is critical since TEF3 functions primarily in the nucleus. Use specialized nuclear extraction buffers with protease inhibitors to prevent degradation.

• Gel percentage: Use 8-10% SDS-PAGE gels for separating TEF3 (approximately 70-75 kDa).

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody dilution: Most TEF3 antibodies work optimally at 1:500-1:2000 dilution. The C-terminal targeting antibody (AA 489-516) has been specifically validated for Western blotting applications .

• Incubation conditions: Incubate with primary antibody overnight at 4°C with gentle agitation.

• Detection system: HRP-conjugated secondary antibodies with enhanced chemiluminescence (ECL) detection provide good sensitivity for TEF3 detection.

• Controls: Include positive controls (tissues/cells known to express TEF3) and negative controls (knockdown cells where TEF3 expression is reduced).

For detecting specific isoforms like TEF3-1, which has been implicated in cell cycle progression, choose antibodies that can distinguish between different isoforms .

How can I effectively use TEF3 antibodies to investigate transcriptional regulation in angiogenesis?

To investigate TEF3's role in transcriptional regulation during angiogenesis:

• Chromatin Immunoprecipitation (ChIP): Use TEF3 antibodies for ChIP assays to identify direct binding targets. For example, TEF3 has been shown to directly interact with the M-CAT site in the DSCR1-1L promoter both in vitro and in vivo . Design PCR primers according to sequences of putative M-CAT binding sites in your gene of interest. For DSCR1-1L promoter analysis, researchers have successfully used primers targeting the proximal portion of the promoter (forward: 5′-AGTACATTGGTTTGGTCTG and reverse: 5′-ACGGTTCTATGATTACTATTAT) .

• Tube formation assays: After modulating TEF3 expression (overexpression or knockdown), use HUVECs in Matrigel tube formation assays to assess angiogenic potential. Microarray analysis has confirmed that TEF3-1 overexpression upregulates genes related to angiogenesis promotion .

• Combinatorial approach: Combine immunofluorescence with TEF3 antibodies and markers of angiogenesis to evaluate co-expression patterns in tumor tissues. High nuclear expression of TEF3-1 has been observed during vascular structure formation in gastric cancer .

• In vivo validation: Use xenograft models to assess how TEF3 modulation affects tumor angiogenesis. Knockdown of TEF3-1 has been shown to suppress both tumor growth and angiogenesis in such models .

• Target gene analysis: After identifying TEF3 binding sites, evaluate the expression of target genes using RT-PCR and Western blotting to confirm functional regulation.

What are the challenges in distinguishing between different TEF family members using antibodies?

Distinguishing between TEF family members presents several challenges:

• Structural similarity: TEF family members (TEF1, TEF3, TEF4, TEF5) share significant sequence homology, particularly in their DNA-binding domains, making specific detection challenging.

• Isoform complexity: TEF3 itself has multiple isoforms (such as TEF3-1 and TEF3-3) with different functions. For instance, overexpression of TEF3 isoform 1, but not isoform 3, in HUVEC was sufficient to induce DSCR1-1L expression even without VEGF-A165 stimulation .

• Cross-reactivity testing: Always validate antibody specificity by testing against recombinant proteins of all TEF family members. Immunoprecipitation assays with antibodies against TEF1, TEF3, TEF4, and TEF5 have been used to differentiate between family members .

• Controls: Include TEF3 knockdown samples as negative controls to confirm antibody specificity. Lentiviral-mediated siRNAs targeting TEF3-1 have been shown to effectively downregulate TEF3-1 expression in HUVECs .

• Epitope selection: Choose antibodies targeting unique regions of TEF3 that differ from other family members. C-terminal targeting antibodies (AA 489-516) may provide better specificity than those targeting more conserved domains .

• Validation methods: Confirm specificity through multiple techniques (Western blot, immunoprecipitation, mass spectrometry) to ensure reliable results.

How can TEF3 antibodies be used to investigate the role of TEF3 in cell cycle regulation?

To investigate TEF3's role in cell cycle regulation:

• Cell synchronization studies: Synchronize cells at different cell cycle phases and assess TEF3 expression and localization using specific antibodies. Nuclear localization of TEF3-1 has been shown to promote G1/S transition in HUVECs .

• Flow cytometry: Combine TEF3 antibody staining with DNA content analysis to correlate TEF3 expression with specific cell cycle phases. Knockdown of TEF3-1 has been shown to delay G1 to S phase transition .

• Co-immunoprecipitation: Use TEF3 antibodies to pull down protein complexes and identify cell cycle-related binding partners.

• Expression analysis: Following TEF3 modulation, assess the expression of cell cycle regulators. When TEF3-1 is overexpressed, the expression levels of cyclins and CDKs are upregulated, while knockdown of TEF3-1 leads to downregulation of cyclins and CDKs and upregulation of P21, a negative regulator of the cell cycle .

• Rescue experiments: After TEF3 knockdown, perform rescue experiments with different TEF3 constructs to identify domains critical for cell cycle regulation.

Microarray analysis has shown that TEF3-1 affects the expression of numerous cell cycle-related genes, including cyclins, cyclin-dependent kinases (CDKs), and cell division control (CDC) proteins, confirming its central role in cell cycle progression .

What are the best practices for validating TEF3 antibody specificity?

To validate TEF3 antibody specificity:

• Positive and negative controls: Use tissues/cells known to express TEF3 as positive controls. For negative controls, use knockdown models where TEF3 expression is reduced using lentiviral-mediated siRNAs .

• Multiple antibodies: Test multiple antibodies targeting different epitopes of TEF3. Compare antibodies targeting different regions, such as C-terminal (AA 489-516), N-terminal (AA 1-30), and internal regions .

• Peptide competition: Pre-incubate the antibody with the immunizing peptide before application to demonstrate binding specificity.

• Western blot analysis: Confirm the antibody detects a band of the expected molecular weight. For TEF3, look for a band at approximately 70-75 kDa.

• Immunoprecipitation followed by mass spectrometry: This gold standard approach confirms that the antibody is pulling down the correct protein.

• Knockout/knockdown validation: Compare staining patterns in wild-type versus TEF3 knockout or knockdown samples. Various lentiviral-mediated siRNAs (such as LV-SiTEF3-1#1, LV-SiTEF3-1#2, and LV-SiTEF3-1#3) have been used to suppress TEF3-1 protein in HUVECs .

• Cross-species reactivity: Test the antibody across different species to confirm expected conservation patterns. Some TEF3 antibodies have been validated for reactivity with both human and mouse samples .

How do I address inconsistent results when using TEF3 antibodies in different experimental contexts?

When encountering inconsistent results with TEF3 antibodies:

• Antibody validation: Re-validate antibody specificity using Western blotting and known positive/negative controls.

• Epitope accessibility: Consider that post-translational modifications or protein-protein interactions might mask the epitope in certain contexts. Try different antibodies targeting different epitopes of TEF3 .

• Fixation sensitivity: Test different fixation methods as some epitopes are fixation-sensitive. Compare paraformaldehyde, methanol, and acetone fixation for immunofluorescence applications.

• Subcellular localization: TEF3 functions may depend on its nuclear localization . Ensure your protein extraction method efficiently captures nuclear proteins if studying nuclear TEF3.

• Isoform specificity: Verify which TEF3 isoform your antibody detects. TEF3 has multiple isoforms with different functions - for example, TEF3 isoform 1, but not isoform 3, induces DSCR1-1L expression in HUVECs .

• Experimental conditions: Standardize cell culture conditions, as TEF3 expression and localization may be affected by cell density, serum concentration, and growth factors.

• Technical variables: Ensure consistent antibody concentrations, incubation times, and detection methods across experiments.

What are the key considerations when using TEF3 antibodies for studying protein-DNA interactions?

When studying TEF3-DNA interactions:

• Antibody selection: Choose ChIP-validated TEF3 antibodies. Antibodies used successfully in chromatin immunoprecipitation assays are more likely to recognize the native protein-DNA complex .

• Crosslinking optimization: Optimize formaldehyde concentration (typically 1%) and crosslinking time (8-10 minutes) for efficient but reversible protein-DNA crosslinking.

• Sonication parameters: Carefully optimize sonication conditions to generate DNA fragments of appropriate size (200-500 bp) for effective immunoprecipitation and subsequent analysis.

• Controls: Include input control (pre-immunoprecipitation chromatin), IgG control (non-specific antibody), and positive control (antibody against a known DNA-binding protein). In previous research, IgG has been used as a control in immunoprecipitation experiments with TEF3 .

• Sequential ChIP: For studying complex transcriptional regulators, perform sequential ChIP with antibodies against TEF3 and its binding partners.

• Binding site verification: Confirm TEF3 binding sites using techniques like EMSA or reporter assays. TEF3 has been shown to directly interact with M-CAT sites in promoter regions, such as the DSCR1-1L promoter .

• Data analysis: Use appropriate controls and statistical methods to identify genuine binding sites. After immunoprecipitation, the chromosomal DNA can be extracted with phenol-chloroform and analyzed by PCR using primers designed according to the sequences of putative binding sites .

How can TEF3 antibodies be utilized in cancer research and potential therapeutic applications?

TEF3 antibodies offer several applications in cancer research:

• Biomarker development: Use TEF3 antibodies to assess nuclear TEF3 expression as a potential biomarker for cancer progression. Nuclear TEF3-1 has been identified as a potential oncogenic biomarker in HUVECs .

• Tumor angiogenesis research: Apply TEF3 antibodies to investigate the protein's role in tumor vascularization. High nuclear expression of TEF3-1 has been observed during vascular structure formation in gastric cancer, and knockdown of TEF3-1 suppresses tumor growth and angiogenesis .

• Patient stratification: Develop immunohistochemistry protocols using TEF3 antibodies to potentially stratify patients for personalized treatments based on TEF3 expression patterns.

• Therapeutic target validation: Use TEF3 antibodies to monitor changes in TEF3 expression or localization following treatment with potential anti-cancer agents. The suppression of TEF3-1 may be a potential target in anti-tumor therapy .

• Mechanism studies: Investigate the effects of TEF3 modulation on downstream targets like cyclins and CDKs that promote cancer cell proliferation. Microarray analysis has confirmed that TEF3-1 overexpression upregulates genes related to cell cycle progression .

• Combination therapy research: Assess how TEF3 inhibition might synergize with other cancer treatments, particularly those targeting angiogenesis.

What methodological approaches can be used to study the interaction between TEF3 and other transcription factors?

To study TEF3 interactions with other transcription factors:

• Co-immunoprecipitation (Co-IP): Use TEF3 antibodies to pull down protein complexes, followed by Western blotting to detect interacting partners.

• Proximity ligation assay (PLA): Combine antibodies against TEF3 and potential binding partners to visualize protein-protein interactions in situ with single-molecule resolution.

• Bimolecular fluorescence complementation (BiFC): Express TEF3 and potential interacting proteins as fusion proteins with complementary fragments of a fluorescent protein to visualize interactions in living cells.

• FRET/FLIM analysis: Use fluorescently labeled antibodies against TEF3 and interacting partners to measure Förster resonance energy transfer as evidence of protein proximity.

• Sequential ChIP (ChIP-reChIP): Perform successive immunoprecipitations with antibodies against TEF3 and other transcription factors to identify co-occupied genomic regions. This approach has been used to study transcription factor complexes binding to specific DNA regions .

• Mass spectrometry: Immunoprecipitate TEF3 complexes and identify interacting proteins through mass spectrometry.

• Yeast two-hybrid screening: Use this as a complementary approach to identify novel TEF3 interacting partners.

How can TEF3 antibodies be used to study the differential functions of TEF3 isoforms?

To study differential functions of TEF3 isoforms:

• Isoform-specific antibodies: Use antibodies that specifically recognize different TEF3 isoforms. For example, antibodies targeting unique regions of TEF3-1 versus TEF3-3 .

• Expression analysis: Perform Western blotting with isoform-specific antibodies to assess differential expression of TEF3 isoforms across tissues or experimental conditions.

• Subcellular localization: Use immunofluorescence with isoform-specific antibodies to determine whether different TEF3 isoforms localize to distinct cellular compartments. Nuclear localization of TEF3-1 has been shown to be particularly important for its function in cell cycle progression .

• Isoform-specific knockdown: Design siRNAs targeting unique regions of specific isoforms, then validate knockdown specificity using isoform-specific antibodies.

• Rescue experiments: After knockdown of all TEF3 isoforms, perform rescue experiments with individual isoforms to identify isoform-specific functions. Research has shown that TEF3 isoform 1, but not isoform 3, can induce DSCR1-1L expression in HUVECs even without VEGF-A165 stimulation .

• ChIP-seq comparison: Perform ChIP-seq using isoform-specific antibodies to identify unique and shared genomic binding sites between isoforms.

• Transcriptome analysis: Compare gene expression changes following modulation of specific TEF3 isoforms to identify isoform-specific transcriptional programs.

What are the critical factors in quantifying TEF3 expression levels using antibody-based techniques?

For accurate quantification of TEF3 expression:

• Antibody validation: Ensure linearity of signal over a range of protein concentrations to establish the quantitative range of your assay.

• Loading controls: Use appropriate loading controls (β-actin for cytoplasmic, histone H3 for nuclear fractions) to normalize TEF3 expression.

• Signal detection: Use digital imaging systems with a wide dynamic range to capture signals accurately. Avoid film exposure which has limited dynamic range.

• Standardization: Include standard curves using recombinant TEF3 protein of known concentrations.

• Nuclear extraction efficiency: Since TEF3 functions primarily in the nucleus, ensure consistent and efficient nuclear protein extraction for comparable results .

• Isoform consideration: Account for which TEF3 isoforms your antibody detects. Some antibodies may recognize multiple isoforms with different molecular weights.

• Statistical analysis: Apply appropriate statistical methods for comparing TEF3 expression across experimental conditions.

• Normalization strategy: When analyzing TEF3 expression in tissues, normalize to cell-type-specific markers rather than housekeeping genes.

How can I correlate TEF3 expression with functional outcomes in angiogenesis and cell cycle progression?

To correlate TEF3 expression with functional outcomes:

• Expression gradients: Create cellular models with varying levels of TEF3 expression (low, medium, high) and assess corresponding functional outcomes.

• Temporal analysis: Track TEF3 expression over time alongside functional readouts to establish temporal relationships.

• Functional assays:

  • For angiogenesis: Tube formation assays, scratch wound healing, and sprouting assays with HUVECs

  • For cell cycle: EdU incorporation, cell cycle analysis by flow cytometry, and measurement of cyclins/CDKs expression

• Correlation analysis: Use statistical methods to correlate TEF3 expression levels with functional parameters. Research has shown that knockdown of TEF3-1 decreases the expression levels of cyclin E and CDKs while increasing P21 expression, correlating with delayed G1 to S phase transition .

• Dose-response relationships: Establish whether functional outcomes show linear or threshold responses to changes in TEF3 levels.

• Multivariate analysis: Consider multiple variables (TEF3 expression, subcellular localization, isoform ratios) when correlating with functional outcomes.

• In vivo validation: Confirm in vitro findings using animal models with modulated TEF3 expression. Tumor xenograft experiments have shown that TEF3-1 knockdown suppresses both tumor growth and angiogenesis .

What are the best approaches for integrating TEF3 antibody data with genomic and transcriptomic datasets?

To integrate TEF3 antibody data with genomic/transcriptomic datasets:

• ChIP-seq and RNA-seq correlation: Compare TEF3 binding sites (ChIP-seq) with gene expression changes (RNA-seq) to identify direct transcriptional targets.

• Pathway analysis: Use bioinformatic tools to identify enriched pathways in TEF3-regulated genes. Microarray analysis has shown that when TEF3-1 is overexpressed in HUVECs, cell cycle and angiogenesis are among the important pathways affected .

• Motif analysis: Identify DNA motifs enriched in TEF3 binding sites to refine understanding of TEF3 binding preferences. TEF3 has been shown to interact with M-CAT sites in promoter regions .

• Multi-omics integration: Combine TEF3 protein data with transcriptomics, epigenomics, and proteomics data to build comprehensive regulatory networks.

• Single-cell approaches: Apply single-cell technologies to correlate TEF3 protein levels with transcriptional states at the single-cell level.

• Network analysis: Use protein-protein interaction networks to place TEF3 in broader regulatory contexts.

• Temporal dynamics: Integrate time-course data of TEF3 binding with corresponding transcriptional changes to establish cause-effect relationships.

• Comparative analysis: Compare TEF3 regulatory networks across different cell types or disease states to identify context-specific functions.